David Kirn, 4D Molecular Therapeutics CEO
4DMT builds out case for wet AMD gene therapy with new Phase 2 data
4D Molecular Therapeutics presented new Phase 2 data for its wet AMD gene therapy, showing a durable response in a broad patient population, as it …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
